Mateon Therapeutics Inc (MATN) financial statements (2021 and earlier)

Company profile

Business Address 701 GATEWAY BLVD.
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including: 111227307
Cash and cash equivalents 11427307
Short-term investments   9   
Other undisclosed cash, cash equivalents, and short-term investments   (0)   
Prepaid expense   2 00
Other current assets     00
Other undisclosed current assets 0000  
Total current assets: 111427307
Noncurrent Assets
Property, plant and equipment  00000
Intangible assets, net (including goodwill)      0
Intangible assets, net (excluding goodwill)      0
Other noncurrent assets  0000 
Total noncurrent assets:  00000
TOTAL ASSETS: 111427307
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 112121
Accounts payable 110000
Accrued liabilities 00000 
Employee-related liabilities 001110
Other undisclosed current liabilities 0101(0)1
Total current liabilities: 122211
Noncurrent Liabilities
Total liabilities: 122211
Stockholders' equity
Stockholders' equity attributable to parent (0)(0)1325296
Common stock 000000
Additional paid in capital 294292291290280244
Accumulated deficit (295)(292)(278)(265)(251)(239)
Total stockholders' equity: (0)(0)1325296
TOTAL LIABILITIES AND EQUITY: 111427307

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues
(Revenue, Net)
      0
Cost of revenue
(Cost of Goods and Services Sold)
     (3)(3)
Gross profit:     (3)(2)
Operating expenses (3)(14)(14)(14)(13)(8)
Other undisclosed operating income     33
Operating loss: (3)(14)(14)(14)(13)(8)
Nonoperating income 000000
Investment income, nonoperating 000000
Other nonoperating income (expense) (0)(0)(0)0(0)(0)
Loss before gain (loss) on sale of properties: (3)(14)(14)(14)(13)(8)
Other undisclosed net income 0     
Net loss attributable to parent: (3)(14)(14)(14)(13)(8)
Preferred stock dividends and other adjustments      (5)
Net loss available to common stockholders, diluted: (3)(14)(14)(14)(13)(13)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss: (3)(14)(14)(14)(13)(8)
Comprehensive loss, net of tax, attributable to parent: (3)(14)(14)(14)(13)(8)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: